Središnja Medicinska Knjižnica

[1]  M. Korostyński,et al.  The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord , 2011, Neuroscience.

[2]  T. Shin,et al.  Intrathecal Administration of Botulinum Neurotoxin Type A Attenuates Formalin-Induced Nociceptive Responses in Mice , 2011, Anesthesia and analgesia.

[3]  F. Pavone,et al.  Botulinum Neurotoxin for Pain Management: Insights from Animal Models , 2010, Toxins.

[4]  E. Straface,et al.  Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models , 2010, Neuroscience.

[5]  A. Fuglsang-Frederiksen,et al.  The role of botulinum toxin in management of pain: an evidence-based review , 2010, Current opinion in anaesthesiology.

[6]  M. Brin,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.

[7]  M. Salković-Petrisic,et al.  Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. , 2010, European journal of pharmacology.

[8]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.

[9]  L. Bach-Rojecky,et al.  Central origin of the antinociceptive action of botulinum toxin type A , 2009, Pharmacology Biochemistry and Behavior.

[10]  D. Truong,et al.  Current clinical applications of botulinum toxin. , 2009, Current pharmaceutical design.

[11]  P. Chabrier,et al.  Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. , 2009, European journal of pharmacology.

[12]  S. Ovsepian,et al.  Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential , 2009, The Journal of Neuroscience.

[13]  Y. Yamamoto,et al.  Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction , 2009, Neuroscience.

[14]  M. Dominis,et al.  Lack of anti‐inflammatory effect of botulinum toxin type A in experimental models of inflammation , 2008, Fundamental & clinical pharmacology.

[15]  M. Alexiades-Armenakas.  Retrograde transport and transcytosis of botulinum toxin serotypes to the brain: analysis of potential neurotoxicity. , 2008, Journal of drugs in dermatology : JDD.

[16]  M. Caleo,et al.  Long-Distance Retrograde Effects of Botulinum Neurotoxin A , 2008, The Journal of Neuroscience.

[17]  S. Aurora,et al.  Botulinum Toxin Type A Prophylactic Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Exploratory Study , 2006, Headache.

[18]  A. Berardelli,et al.  Clinical value of botulinum toxin in neurological indications , 2006, European journal of neurology.

[19]  K. Aoki.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. , 2005, Neurotoxicology.

[20]  M. Iadarola,et al.  Peripheral targeting of the trigeminal ganglion via the infraorbital foramen as a therapeutic strategy. , 2005, Brain research. Brain research protocols.

[21]  J. Carruthers,et al.  Botulinum toxin type A. , 2005, Journal of the American Academy of Dermatology.

[22]  L. Maffei,et al.  Antiepileptic Effects of Botulinum Neurotoxin E , 2005, The Journal of Neuroscience.

[23]  L. Bach-Rojecky,et al.  Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. , 2005, Croatian medical journal.

[24]  L. Bach-Rojecky,et al.  Botulinum toxin type A in experimental neuropathic pain , 2005, Journal of Neural Transmission.

[25]  P. Raboisson,et al.  The orofacial formalin test , 2004, Neuroscience & Biobehavioral Reviews.

[26]  K. Aoki,et al.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain , 2004, Pain.

[27]  C. Schengrund,et al.  Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. , 2001, Toxicon : official journal of the International Society on Toxinology.

[28]  S. Florence,et al.  Topography of primary afferent projections in the trigeminal sensory nuclei of rats. , 1995, Acta neurobiologiae experimentalis.

[29]  D. Dessem,et al.  Central connections of trigeminal primary afferent neurons: topographical and functional considerations. , 1992, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[30]  M. Jacquin,et al.  Trigeminal projections to contralateral dorsal horn: central extent, peripheral origins, and plasticity. , 1990, Somatosensory & motor research.

[31]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[32]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .